Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...
If you have COPD, there are some things that can cause the disease to flare up. This is referred to as “COPD exacerbation.” Some of the most common causes of COPD exacerbation include: When you have ...
Lower risk for COPD exacerbations seen with SGLT-2 inhibitors and GLP-1 receptor agonists, but not with DPP-4 inhibitors. HealthDay News — For patients with type 2 diabetes (T2D) and chronic ...
Imaging and clinical characteristics reach high diagnostic efficacy when they are used to identify frequent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). A mix of ...
Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...
Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...
Red blood cell distribution width (RDW) may be a good biomarker for chronic obstructive pulmonary disease (COPD) severity, study finds. There is a positive association between increased red blood cell ...
SAN DIEGO -- The beta-blocker bisoprolol did not improve exacerbations in chronic obstructive pulmonary disease (COPD) patients, a randomized clinical trial found. Exacerbations requiring antibiotics, ...
Erdosteine is a multimechanism, mucolytic agent that decreases the sputum viscoelastic properties and bacterial adhesion to the cell membrane, endowed with bronchial anti-inflammatory activity and a ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results